JNJ-5207852

{{Chembox-lat | verifiedrevid = 415670235 | ImageFile = JNJ5207852_structure.png | ImageSize = 200px | PIN = 1-{3-[4-(Piperidin-1-ilmetil)fenoksi]propil}piperidin | SystematicName = 1-({4-[3-(Piperidin-1-il)propoksi]Fenil}metil)piperidin | IUPACName = | Section1 = ! colspan=2 style="background: #f8eaba; text-align: center;" |Identifikacija

|-

|

3D model (Jmol)

|

|-

| Abrevijacija | JNJ-5207852 |-

| ChEBI

|

CHEBI:312531^Y

|-

| ChemSpider

|

2046959^Y

|-

| MeSH | JNJ-5207852 |-

|

PubChem^[1]^[2] C ID

|

2766326

|-

| align="center" colspan="2" | |-

| colspan="2" |

SMILES

O(c1ccc(cc1)CN2CCCCC2)CCCN3CCCCC3
O(c1ccc(cc1)CN2CCCCC2)CCCN3CCCCC3

|- |Section2=! colspan=2 style="background: #f8eaba; text-align: center;" |Svojstva

|-

|

Hemijska formula

| C₂₀H₃₂N₂O

|- | Molarna masa

| 316,480 g/mol

|- |Section3= }}

JNJ-5207852 je histaminski antagonist koji je selektivan za H₃ receptor. On ima stimulantne i nootropne efekte u životinjskim studijama,^[3] te se smatra da on može da bude koristan u tretmanu deficita memorije vezanog za epilepsiju.^[4] JNJ-5207852 nije dospeo do stupnja kliničkog razvoja zbog nepovoljnih farmakokinetičkih karakteristika, ali je srodno jedinjenje JNJ-17216498 trenutno u fazi II kliničkih ispitivanja za tretman narkolepsije.^[5]

Reference[уреди | уреди извор]

^ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003. уреди
^ Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1.
^ Barbier, AJ; Berridge C; Dugovic C; et al. (2004). „Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist”. Br. J. Pharmacol. 143 (5): 649—61. PMC 1575430 . PMID 15466448. doi:10.1038/sj.bjp.0705964.
^ Jia F, Kato M, Dai H, Xu A, Okuda T, Sakurai E, Okamura N, Lovenberg TW, Barbier A, Carruthers NI, Iinuma K, Yanai K. Effects of histamine H(3) antagonists and donepezil on learning and mnemonic deficits induced by pentylenetetrazol kindling in weanling mice. Neuropharmacology. 2006 Mar;50(4):404-11. PMID 16310812
^ Esbenshade TA, Browman KE, Bitner RS, Strakhova M, Cowart MD, Brioni JD (2008). „The histamine H3 receptor: an attractive target for the treatment of cognitive disorders”. Br. J. Pharmacol. 154 (6): 1166—81. PMC 2483387 . PMID 18469850. doi:10.1038/bjp.2008.147.

Spoljašnje veze[уреди | уреди извор]

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003. уреди

[2] Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1.

[pmid15466448-3] Barbier, AJ; Berridge C; Dugovic C; et al. (2004). „Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist”. Br. J. Pharmacol. 143 (5): 649—61. PMC 1575430 . PMID 15466448. doi:10.1038/sj.bjp.0705964.

[4] Jia F, Kato M, Dai H, Xu A, Okuda T, Sakurai E, Okamura N, Lovenberg TW, Barbier A, Carruthers NI, Iinuma K, Yanai K. Effects of histamine H(3) antagonists and donepezil on learning and mnemonic deficits induced by pentylenetetrazol kindling in weanling mice. Neuropharmacology. 2006 Mar;50(4):404-11. PMID 16310812

[pmid18469850-5] Esbenshade TA, Browman KE, Bitner RS, Strakhova M, Cowart MD, Brioni JD (2008). „The histamine H3 receptor: an attractive target for the treatment of cognitive disorders”. Br. J. Pharmacol. 154 (6): 1166—81. PMC 2483387 . PMID 18469850. doi:10.1038/bjp.2008.147.

[1]

[2]

[3]

[4]

[5]